The European consensus on hepatitis C
The European Association for the Study of the Liver (EASL) International Consensus on Hepatitis C made by 72 experts in hepatology, epidemiology and virology at the EASL Consensus Conference, Paris, February, 1999 and confirmed by the 34th EASL Annual Meeting, Naples, 8-12 april 1999, is widely reviewed. Some newest and more effective strategies for treatment of the chronic viral hepatitis C were discussed during the Naples EASL meeting. Higher doses interferons (interferon-alpha or consensus interferon) plus ribavirin (or combination ribavirin and amantadine) for a longer period--12 months, improved efficacy of the treatment of chronic hepatitis C. An ultrarapid HCV clearance by daily hgh-dose interferon-alpha induction therapy in the start of the management plus ribavirin was achieved and discussed in naive patients and in nonresponders to standard therapy. A gene therapy by an effective genetic vaccine against HCV infection was widely discussed, too. Hepatitis C is an enormous present and future health burden to the world. Not until 2010, the most of therapeutic problems in patients with chronic persisted HCV infection would be resolved.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1999 |
|---|---|
| Erschienen: |
1999 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Vutreshni bolesti - 31(1999), 4 vom: 20., Seite 21-8 |
| Sprache: |
Bulgarisch |
|---|
| Weiterer Titel: |
Evropeĭski konsensus za khepatit C |
|---|
| Beteiligte Personen: |
Kolarski, V [VerfasserIn] |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 02.10.2000 Date Revised 16.11.2017 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM109099028 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM109099028 | ||
| 003 | DE-627 | ||
| 005 | 20231222150618.0 | ||
| 007 | tu | ||
| 008 | 231222s1999 xx ||||| 00| ||bul c | ||
| 028 | 5 | 2 | |a pubmed24n0364.xml |
| 035 | |a (DE-627)NLM109099028 | ||
| 035 | |a (NLM)10989671 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a bul | ||
| 100 | 1 | |a Kolarski, V |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The European consensus on hepatitis C |
| 246 | 3 | 3 | |a Evropeĭski konsensus za khepatit C |
| 264 | 1 | |c 1999 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2000 | ||
| 500 | |a Date Revised 16.11.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The European Association for the Study of the Liver (EASL) International Consensus on Hepatitis C made by 72 experts in hepatology, epidemiology and virology at the EASL Consensus Conference, Paris, February, 1999 and confirmed by the 34th EASL Annual Meeting, Naples, 8-12 april 1999, is widely reviewed. Some newest and more effective strategies for treatment of the chronic viral hepatitis C were discussed during the Naples EASL meeting. Higher doses interferons (interferon-alpha or consensus interferon) plus ribavirin (or combination ribavirin and amantadine) for a longer period--12 months, improved efficacy of the treatment of chronic hepatitis C. An ultrarapid HCV clearance by daily hgh-dose interferon-alpha induction therapy in the start of the management plus ribavirin was achieved and discussed in naive patients and in nonresponders to standard therapy. A gene therapy by an effective genetic vaccine against HCV infection was widely discussed, too. Hepatitis C is an enormous present and future health burden to the world. Not until 2010, the most of therapeutic problems in patients with chronic persisted HCV infection would be resolved | ||
| 650 | 4 | |a Consensus Development Conference | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Viral Hepatitis Vaccines |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Vutreshni bolesti |d 1971 |g 31(1999), 4 vom: 20., Seite 21-8 |w (DE-627)NLM000055662 |x 0506-2772 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:1999 |g number:4 |g day:20 |g pages:21-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 1999 |e 4 |b 20 |h 21-8 | ||